Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Multiple Sclerosis Drugs Market In 2029?

There has been significant expansion in the size of the multiple sclerosis drugs market in the previous few years. The market, which is projected to increase from $29.66 billion in 2024 to $31.5 billion in 2025, foresees a compound annual growth rate (CAGR) of 6.2%. The primary drivers of growth during the historic period were increased instances of multiple sclerosis, unfulfilled healthcare needs, substantial investments from pharmaceutical companies, and heightened awareness about multiple sclerosis.

What Growth Rate Is Forecasted for the Multiple Sclerosis Drugs Market by 2029?

The market size of drugs for multiple sclerosis is anticipated to experience a swift expansion in the forthcoming years. The market’s valuation is projected to surge to $47.97 billion by 2029, propelled at a compound annual growth rate (CAGR) of 11.1%. Factors contributing to the growth during the forecast period include the growing availability of clinical trials, targeted treatments, preventative medicine, expanding demand for biosimilars, and wide-ranging geographical reach, along with combination treatments. Key trends to look out for during this period include the increasing use of immunomodulatory drugs, prolonged-action formulations, patient-centered care, drug innovation, and oral and infusion therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2817&type=smp

Which Key Companies Are Shaping the Future of the Multiple Sclerosis Drugs Market?

Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd, EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

Which Factors Are Driving Demand in the Multiple Sclerosis Drugs Industry?

The advancement of the multiple sclerosis drugs market is propelled by the backing of both governmental and non-governmental entities. Government and non-government organizations offer financial aid through a range of schemes and initiatives to improve the lives of those battling multiple sclerosis (MS). For example, the Alberta government along with the Department of Economic Development, Trade, and Tourism in Canada, contributed $1 million to the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). This support is aimed at driving research and innovation to expand understanding and treatments for MS. CanProCo represents a collaboration of around 50 MS researchers from various disciplines throughout Canada. Additional funding was provided by Canada Brain Research, Biogen Canada, and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada), collectively raising a total of $10 million. This significant financial backing from both governmental and non-governmental organizations stimulates the progression of the multiple sclerosis drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2817&type=smp

How Is the Multiple Sclerosis Drugs Market Segmented by Several Divisions?

The multiple sclerosis drugs market covered in this report is segmented –

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes

2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores

3) By Route Of Administration: Oral Drugs, Parenteral Drugs

Subsegments:

1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate

2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab

3) By Interferons: Interferon Beta-1a, Interferon Beta-1b

4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies

What are the Emerging Market Trends Driving the Growth of the Multiple Sclerosis Drugs Industry?

Firms are swiftly intensifying their initiative to concentrate on new product launches to accommodate the growing demands for multiple sclerosis (MS) drugs. Multiple sclerosis necessitates long-term therapy, which raises the total cost of treating a patient. In response, firms in the multiple sclerosis market are creating medicines specifically for treating this condition. In line with this trend, the FDA has given the green light to Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Both medications were introduced as orally taken drugs for ease of consumption.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Which Regions Are Driving Growth in the Multiple Sclerosis Drugs Market?

The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2817

This Report Delivers Insight On:

1. How big is the multiple sclerosis drugs market, and how is it changing globally?

2. Who are the major companies in the multiple sclerosis drugs market, and how are they performing?

3. What are the key opportunities and risks in the multiple sclerosis drugs market right now?

4. Which products or customer segments are growing the most in the multiple sclerosis drugs market?

5. What factors are helping or slowing down the growth of the multiple sclerosis drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model